These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 18691521)

  • 1. EU borderline cosmetic products review of current regulatory status.
    Morganti P; Paglialunga S
    Clin Dermatol; 2008; 26(4):392-7. PubMed ID: 18691521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of cosmetics in the EU. Reality and challenges for the toxicologist.
    Pauwels M; Rogiers V
    Toxicol Lett; 2004 Jun; 151(1):7-17. PubMed ID: 15177635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cosmetic products and their current European regulatory framework.
    Rogiers V; Pauwels M
    Curr Probl Dermatol; 2008; 36():1-28. PubMed ID: 18806452
    [No Abstract]   [Full Text] [Related]  

  • 5. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.
    Adler S; Basketter D; Creton S; Pelkonen O; van Benthem J; Zuang V; Andersen KE; Angers-Loustau A; Aptula A; Bal-Price A; Benfenati E; Bernauer U; Bessems J; Bois FY; Boobis A; Brandon E; Bremer S; Broschard T; Casati S; Coecke S; Corvi R; Cronin M; Daston G; Dekant W; Felter S; Grignard E; Gundert-Remy U; Heinonen T; Kimber I; Kleinjans J; Komulainen H; Kreiling R; Kreysa J; Leite SB; Loizou G; Maxwell G; Mazzatorta P; Munn S; Pfuhler S; Phrakonkham P; Piersma A; Poth A; Prieto P; Repetto G; Rogiers V; Schoeters G; Schwarz M; Serafimova R; Tähti H; Testai E; van Delft J; van Loveren H; Vinken M; Worth A; Zaldivar JM
    Arch Toxicol; 2011 May; 85(5):367-485. PubMed ID: 21533817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expected change of direction in Polish law regarding cosmetics].
    Karłowski K; Smietanka B; Biernat U; Burzyńska I; Pawłowska K
    Rocz Panstw Zakl Hig; 2004; 55(1):21-5. PubMed ID: 15307612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CE marking & the MDD: what difference will the new regulations make?
    Lindley E
    EDTNA ERCA J; 1996; 22(1):29-30. PubMed ID: 10723308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cosmetics, categories, and the future.
    Draelos ZD
    Dermatol Ther; 2012; 25(3):223-8. PubMed ID: 22913438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recalls of microbiologically contaminated cosmetics in EU from 2005 to May 2008.
    Lundov MD; Zachariae C
    Int J Cosmet Sci; 2008 Dec; 30(6):471-4. PubMed ID: 19099548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human health safety evaluation of cosmetics in the EU: a legally imposed challenge to science.
    Pauwels M; Rogiers V
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):260-74. PubMed ID: 20006634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current guidelines applicable for the approval of topically applied dermatological drugs in the EU.
    Straube MD; Zesch A
    Fundam Clin Pharmacol; 2004 Oct; 18(5):503-11. PubMed ID: 15482371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges related to cosmetic safety assessment in the EU.
    Rogiers V; Pauwels M
    Curr Probl Dermatol; 2008; 36():29-57. PubMed ID: 18806453
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs and other product choices.
    Hyman PM; Carvajal R
    Dermatol Ther; 2009; 22(3):216-24. PubMed ID: 19453345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sanitary control of cosmetics].
    Bonini M; Pellino P; Pilla M
    Ig Sanita Pubbl; 2005; 61(3):271-84. PubMed ID: 17206194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical analysis of the safety assessment of cosmetic ingredients performed at the European level.
    Rogiers V; Pauwels M
    Curr Probl Dermatol; 2008; 36():58-93. PubMed ID: 18806454
    [No Abstract]   [Full Text] [Related]  

  • 17. Is the replacement strategy, as it exists today in the EU for cosmetics, the way forward ?
    Rogiers V
    Arch Toxicol; 2011 May; 85(5):363-4. PubMed ID: 21528384
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on cosmeceuticals.
    Kerscher M; Buntrock H
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):314-26; quiz 327. PubMed ID: 21291512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterile by any other name.
    Donawa ME
    Med Device Technol; 1996; 7(1):12-5. PubMed ID: 10172722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A perspective on the safety of cosmetic products: a position paper of the American Council on Science and Health.
    Ross G
    Int J Toxicol; 2006; 25(4):269-77. PubMed ID: 16815815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.